Compare CYRX & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYRX | KBDC |
|---|---|---|
| Founded | 1999 | 2021 |
| Country | United States | United States |
| Employees | 1100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.9M | 855.9M |
| IPO Year | 2008 | 2018 |
| Metric | CYRX | KBDC |
|---|---|---|
| Price | $16.84 | $13.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | $13.31 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 440.9K | 335.1K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 13.16% |
| EPS Growth | ★ 156.22 | N/A |
| EPS | N/A | ★ 0.85 |
| Revenue | ★ $176,177,000.00 | N/A |
| Revenue This Year | $11.06 | $193.84 |
| Revenue Next Year | $8.45 | $9.00 |
| P/E Ratio | ★ N/A | $15.58 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.61 | $12.88 |
| 52 Week High | $17.20 | $15.87 |
| Indicator | CYRX | KBDC |
|---|---|---|
| Relative Strength Index (RSI) | 61.56 | 43.00 |
| Support Level | $14.55 | $12.88 |
| Resistance Level | $16.87 | $14.20 |
| Average True Range (ATR) | 0.55 | 0.23 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 86.56 | 29.89 |
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company, investing mainly in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation mainly through debt investments in middle-market companies.